Hyperfine $HYPR

Health Care · NASDAQ

$0.55
+0.02 (+4.27%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 27, 2026, the first target we tracked for HYPR.

Hyperfine (HYPR) is trading up at $0.55 (+4.27%) on NASDAQ, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Analyst price targets on HYPR

Current price targets from 2 firms average $2 — 266% above the current $0.55. Each is tracked to its date and scored the same way a member's call is.

2 targets, newest first. Open a row for its source and scoring.

DateOct 27, 2026 FirmLucid Capital Markets RatingBuy · initiates Targetat $0.75 · $2 +167% Horizonby Oct 2027 StatusOpen

Entry price $0.75, the close nearest Oct 27, 2026, when the target was reported; the target is +167% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 27, 2027.

Source Lucid Capital Markets initiates Hyperfine stock with buy rating Investing.com · Oct 27, 2026 · opens the publisher's site
Lucid Capital Markets initiated coverage on Hyperfine Inc. (NASDAQ:HYPR) with a buy rating and a price target of $2.00
DateOct 27, 2026 FirmBTIG RatingBuy · reiterates Targetat $0.75 · $2 +167% Horizonby Oct 2027 StatusOpen

Entry price $0.75, the close nearest Oct 27, 2026, when the target was reported; the target is +167% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 27, 2027.

Source Lucid Capital Markets initiates Hyperfine stock with buy rating Investing.com · Oct 27, 2026 · opens the publisher's site
BTIG reiterated its Buy rating and $2.00 price target on Hyperfine

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Hyperfine revenue & net income history (FY2020–FY2025)

RevenueNet incomeNet margin (right axis, %)
$13.6M−$25.6M−$64.9MFY2020 revenue: $294.0KFY2020 net income: −$23.4M · Net margin −7968.4%'20FY2021 revenue: $1.50MFY2021 net income: −$64.9M · Net margin −4335.0%'21FY2022 revenue: $6.81MFY2022 net income: −$44.2M · Net margin −649.2%'22FY2023 revenue: $11.0MFY2023 net income: −$44.2M · Net margin −401.0%'23FY2024 revenue: $12.9MFY2024 net income: −$40.7M · Net margin −315.9%'24FY2025 revenue: $13.6MFY2025 net income: −$35.6M · Net margin −262.3%'25−100%−75%−50%−25%0%FY2020 net margin: −7968.4% (off the scale, which stops at −100.0%)FY2021 net margin: −4335.0% (off the scale, which stops at −100.0%)FY2022 net margin: −649.2% (off the scale, which stops at −100.0%)FY2023 net margin: −401.0% (off the scale, which stops at −100.0%)FY2024 net margin: −315.9% (off the scale, which stops at −100.0%)FY2025 net margin: −262.3% (off the scale, which stops at −100.0%)
Hyperfine annual financial statements
FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$294.0K$1.50M$6.81M$11.0M$12.9M$13.6M
Growth (year over year)—+408.8%+355.5%+61.9%+16.8%+5.2%
Gross profit−$477.0K−$1.17M$907.0K$4.76M$5.89M$6.75M
Gross margin−162.2%−78.0%13.3%43.1%45.7%49.8%
Operating income−$23.5M−$64.9M−$73.9M−$48.1M−$43.2M−$37.1M
Operating margin−7990.1%−4336.1%−1084.2%−436.1%−335.3%−273.4%
Net income−$23.4M−$64.9M−$44.2M−$44.2M−$40.7M−$35.6M
Net margin−7968.4%−4335.0%−649.2%−401.0%−315.9%−262.3%
EPS (diluted)−$15.38−$17.57−$1.04−$0.62−$0.56−$0.43
Balance sheet
Cash and equivalents$62.7M$188.5M$117.5M$75.2M$37.6M$35.1M
Total assets$71.5M$202.5M$134.1M$94.2M$58.9M$55.3M
Total liabilities$4.29M$16.2M$10.3M$9.80M$9.86M$14.3M
Long-term debt—————$0
Shareholders' equity−$61.1M$186.2M$123.7M$84.4M$49.0M$41.0M
Cash flow
Operating cash flow−$21.5M−$47.2M−$72.3M−$41.8M−$38.8M−$27.9M
Capital expenditure$1.57M$2.71M$585.0K$804.0K$383.0K$1.19M
Free cash flow−$23.1M−$49.9M−$72.9M−$42.6M−$39.1M−$29.1M

From Hyperfine's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Hyperfine in the news

Nov 18, 2026 Investing.com B.Riley lowers Hyperfine stock price target on valuation adjustment
Nov 9, 2026 Investing.com Hyperfine earnings beat by $0.02, revenue fell short of estimates
Oct 27, 2026 Investing.com Lucid Capital Markets initiates Hyperfine stock with buy rating Target

About Hyperfine

Headquarters
Guilford, Connecticut From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →